Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,414Revenue $M4.1Net Margin (%)-1,983.7Z-Score24.9
Enterprise Value $M1,139EPS $-1.0Operating Margin %-1,981.1F-Score4
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-1,983.7Higher ROA y-yY
Price/Book5.310-y EBITDA Growth Rate %0Quick Ratio12.1Cash flow > EarningsY
Price/Sales5265-y EBITDA Growth Rate %0Current Ratio12.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-23.5Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-25.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M89.4ROI % (ttm)-48.8Gross Margin Increase y-yY

Gurus Latest Trades with CLDX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CLDXJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$16.95 - $31.59
($25.6)
$ 15.82-38%Sold Out0
CLDXJean-Marie Eveillard 2013-12-31 Reduce-0.04%$21.51 - $36.71
($25.51)
$ 15.82-38%Reduce -75.45%135,000
CLDXJean-Marie Eveillard 2013-06-30 Reduce-0.02%$11.01 - $16.09
($13.13)
$ 15.8220%Reduce -45.89%665,560
CLDXJean-Marie Eveillard 2012-06-30 Add0.02%$3.9 - $5.26
($4.39)
$ 15.82260%Add 260.87%1,660,000
CLDXGeorge Soros 2012-06-30 Sold Out -0.06%$3.9 - $5.26
($4.39)
$ 15.82260%Sold Out0
CLDXGeorge Soros 2012-03-31 Buy 0.06%$2.77 - $5.46
($4)
$ 15.82296%New holding, 803200 sh.803,200
CLDXJean-Marie Eveillard 2012-03-31 Add0.01%$2.77 - $5.46
($4)
$ 15.82296%Add 360%460,000
CLDXJean-Marie Eveillard 2011-12-31 Reduce$2.11 - $3.21
($2.7)
$ 15.82486%Reduce -71.43%100,000
CLDXJean-Marie Eveillard 2011-06-30 Buy 0.01%$3.03 - $4.46
($3.75)
$ 15.82322%New holding, 350000 sh.350,000
CLDXJean-Marie Eveillard 2010-03-31 Sold Out $4.35 - $6.39
($4.93)
$ 15.82221%Sold Out0
CLDXJean-Marie Eveillard 2009-12-31 Buy $4.2 - $5.66
($4.78)
$ 15.82231%New holding, 100000 sh.100,000
CLDXJean-Marie Eveillard 2009-09-30 Sold Out $4.95 - $7.93
($6.35)
$ 15.82149%Sold Out0
CLDXJean-Marie Eveillard 2009-06-30 Buy $6.81 - $11.22
($8.56)
$ 15.8285%New holding, 50000 sh.50,000
CLDXJohn Hussman 2009-06-30 Sold Out $6.81 - $11.22
($8.56)
$ 15.8285%Sold Out0
CLDXJohn Hussman 2008-12-31 Buy $4.94 - $7.81
($6.3)
$ 15.82151%New holding, 13000 sh.13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CLDX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CLDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CATLIN AVERY WSr. VP & CFO 2013-12-06Sell183,333$24.5-36.45 view
ELLBERGER LARRYDirector 2013-12-06Sell17,728$24.5-36.45 view
PENNER HARRY JRDirector 2013-12-06Sell17,728$24.5-36.45 view
LIPTON KAREN SHOOSDirector 2013-12-06Sell17,728$24.5-36.45 view
KELER TIBORSr. VP & CSO 2011-08-11Buy5,000$2.5522.8 view
CATLIN AVERY WSr. VP & CFO 2011-08-09Buy2,000$2.39551.46 view
Marucci Anthony SPresident & CEO 2011-08-09Buy15,000$2.41546.06 view
LIPTON KAREN SHOOSDirector 2010-09-16Buy3,000$3.74316.31 view
Davis Thomas AndrewSr. VP & CMO 2010-09-16Buy2,500$3.77313 view
PAREKH RAJESH RDirector 2010-09-13Buy40,000$3.73317.43 view

Press Releases about CLDX :

    Quarterly/Annual Reports about CLDX:

    News about CLDX:

    Articles On GuruFocus.com
    CLDX up 223%, Cohen Gains Big Apr 23 2013 
    Steve Cohen Increases Celldex Up 145% Apr 06 2013 
    comment on CLDX Mar 06 2013 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
    Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) May 06 2010 
    cooldecency99 note on CLDX May 01 2010 
    CELLDEX THERAPEUTICS, INC (CLDX) CFO Avery W Catlin buys 1,000 Shares Dec 01 2009 


    More From Other Websites
    Celldex Therapeutics (CLDX) Worth Watching: Stock Rises 9.1% Aug 27 2014
    Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX) Aug 22 2014
    5 Companies Developing New Cancer Drugs Aug 19 2014
    CELLDEX THERAPEUTICS, INC. Financials Aug 15 2014
    CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
    CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2014
    Celldex Reports Second Quarter 2014 Results Aug 06 2014
    Q2 2014 Celldex Therapeutics, Inc. Earnings Release - After Market Close Aug 06 2014
    17 stocks traders are shorting ahead of earnings Aug 04 2014
    Celldex Therapeutics Announces Senior Leadership Promotions Jul 30 2014
    Celldex Therapeutics (CLDX) Is Today's Perilous Reversal Stock Jul 24 2014
    Celldex Therapeutics (CLDX) Is Today's Dead Cat Bounce Stock Jul 18 2014
    Celldex to Report Second Quarter 2014 Financial Results and Host Corporate 2014 Objectives Update... Jul 18 2014
    Why Immunotherapies Have Made DelMar's Lead Drug A Necessity In Brain Cancer Jul 15 2014
    5-Star Biotech Stock Watch: Celldex Therapeutics Jun 25 2014
    Today's Perilous Reversal Stock: Celldex Therapeutics (CLDX) Jun 06 2014
    Celldex Therapeutics (CLDX) Soars: Stock Adds 12.6% in Session Jun 06 2014
    Celldex says Varlilumab continues to demonstrate very favorable profile Jun 02 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK